TITLE:
Efficacy and Safety of Vortioxetine and Duloxetine 60 mg Compared Placebo for the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis
AUTHORS:
Masoud Behzadifar, Abouzar Keshavarzi, Abed Tofighian, Mohammad Rastian, Mohammad Zobidi, Ali Akbari Sari
KEYWORDS:
Vortioxetine, Duloxetine 60 mg, Placebo, Major Depressive Disorder, Systematic Review, Meta-Analysis
JOURNAL NAME:
Journal of Behavioral and Brain Science,
Vol.5 No.10,
September
10,
2015
ABSTRACT: Background: Major
depressive disorder is a serious public health problem affecting the lives of
millions in the worldwide and leading causes of disability and disease. This
study aimed to evaluate the efficacy and safety of Vortioxetine and Duloxetine
60 mg compared to placebo for the treatment of major depressive disorder. Method:
We searched the Cochrane library, Pub Med, CRD, Scopus, and Central Register of
Controlled Trials to January 2015. We also searched ClinicalTrials.gov,
International depressive disorder Conference and the Anxiety Disorders and
Depression Conference. We identified that five randomized clinical trials were
ultimately included in a Meta analysis. Data analysis was conducted by
Standardized Mean Differences (SMD) for Montgomery-Åsberg Depression Rating
Scale (MADRS), and Odds Ratio (OR) for adverse events. The SMD and OR reported
by 95% CI. Results: Results showed statistical significance in the MADRS for Vortioxetine
(SMD = ﹣3.29; 95% CI ﹣4.47 to ﹣2.10; I2 = 99.3%) and for
Duloxetine 60 mg (SMD = ﹣6.35; 95% CI ﹣8.84, ﹣3.87; I2 = 99.3%). Results showed that the Vortioxetine 2.5, 5, 10, 15, 20 mg and
overall compared to placebo showed a significance for Nausea and no significance
for diarrhea, dry mouth, dizziness, fatigue and headache. Also results of
Duloxetine 60 mg showed a significant effect for dry mouth, dizziness, fatigue and
nausea. Conclusion: It is necessary to do more studies so as to better assess
and much more powerful than the evidence for the use of this drug in the
treatment of depression.